

Drug Monograph

Drug/Drug **Arnuity[®] Ellipta[®] (fluticasone furoate) powder for**
Class: **inhalation/Inhaled Corticosteroids**
Prepared for: MO HealthNet
Prepared by: Conduent

New Criteria **Revision of Existing Criteria**

Executive Summary

- Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
- Dosage Forms:** Arnuity[®] Ellipta[®] is now supplied as a plastic inhaler containing a foil strip with 30 blisters containing 50 mcg fluticasone furoate per blister.
- Manufacturer:** GlaxoSmithKline, Research Triangle Park, NC 27709
- Indications:** Arnuity[®] Ellipta[®] is indicated for the once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 5 years and older.
- Costs:** \$168.30 per device and 30 blisters of Arnuity[®] Ellipta[®] 50 mcg. Wholesale Acquisition Cost
- Summary of Findings:** This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).
- Status Recommendation:** Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL
- Type of PA Criteria:** Increased Risk of ADE Non-preferred
 Appropriate Indications No PA Required

Prepared By: Luke Boehmer PharmD
Date: August 20, 2018